SCHEMBL5282340

SCHEMBL5282340

Cn1nc(C(F)(F)F)c(C(N)=O)c1Cl

nearest known ligand 0.67

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MEN1 O00255 2/20 0.55
KMT2A Q03164 2/20 0.55
SMN1; SMN2 Q16637 1/20 0.55
CYP1A2 P05177 4/20 0.51
CYP2C19 P33261 3/20 0.51
CYP3A4 P08684 2/20 0.51
ALDH1A1 P00352 1/20 0.51
POLB P06746 1/20 0.51
CYP2C9 P11712 1/20 0.51
LMNA P02545 1/20 0.50
CYP2D6 P10635 2/20 0.43
KDM4E B2RXH2 1/20 0.39
RECQL P46063 1/20 0.39
PSEN1 P49768 1/20 0.38
PSEN2 P49810 1/20 0.38
APH1B Q8WW43 1/20 0.38
NCSTN Q92542 1/20 0.38
APH1A Q96BI3 1/20 0.38
PSENEN Q9NZ42 1/20 0.38
L3MBTL1 Q9Y468 2/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3062142 0.84 MEN1 (0.56) MEN1KMT2ASMN1; SMN2CYP1A2CYP2C19
SCHEMBL841261 0.84 MEN1 (0.56) MEN1KMT2ASMN1; SMN2CYP1A2CYP2C19
SCHEMBL8261356 0.84 MEN1 (0.56) MEN1KMT2ASMN1; SMN2CYP1A2CYP2C19
Hydrochloric Acid SCHEMBL6737822 0.83 MEN1 (0.55) MEN1KMT2ASMN1; SMN2CYP1A2CYP2C19
SCHEMBL24769905 0.83 MEN1 (0.55) MEN1KMT2ASMN1; SMN2CYP1A2CYP2C19
SCHEMBL28040517 0.82 MEN1 (0.61) MEN1KMT2ASMN1; SMN2CYP1A2CYP2C19
SCHEMBL10018238 0.81 KDM4E (0.42) MEN1KMT2ASMN1; SMN2CYP1A2CYP2C19
SCHEMBL31735685 0.81 POLB (0.45) MEN1KMT2ASMN1; SMN2CYP1A2CYP2C19
SCHEMBL27641636 0.81 SMN1; SMN2 (0.43) MEN1KMT2ASMN1; SMN2CYP1A2CYP2C19
SCHEMBL6740724 0.80 MEN1 (0.52) MEN1KMT2ASMN1; SMN2CYP1A2CYP2C19

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-116456831-A Biological insecticide 坎纳尔地球科学有限公司 2023-07-18 CN disclosed
CN-110087460-B Bacillus thuringiensis RTI545 compositions and methods of use for benefiting plant growth and controlling plant pests FMC 公司 2022-06-28 CN disclosed
EP-1363925-B8 MACROLIDE ANTIBIOTICS GLAXO GROUP LTD (GB) 2007-04-25 EP disclosed
CN-1294121-C Substituted anilide derivatives, intermediates thereof, agricultural and horticultural chemicals and their usage NIHON NOHYAKU CO LTD (JP) 2007-01-10 CN disclosed
EP-1363925-B1 MACROLIDE ANTIBIOTICS GLAXO GROUP LTD (GB) 2006-11-15 EP disclosed
US-20060211636-A1 Macrolide Antibiotics ALIHODZIC SULEJMAN 2006-09-21 US disclosed
US-20050215495-A1 Macrolide antibiotics ALIHODZIC SULEJMAN 2005-09-29 US disclosed
CN-1512986-A Substituted anilide derivatives, intermediates thereof, agricultural and horticultural chemicals and their usage �ձ��ݶ�ũҩ��ʽ���� 2004-07-14 CN disclosed
US-20040077557-A1 Macrolide antibiotics GLAXO GROUP LIMITED (GB) 2004-04-22 US disclosed
EP-1363925-A1 MACROLIDE ANTIBIOTICS GLAXO GROUP LIMITED (GB) 2003-11-26 EP disclosed
WO-2002050091-A1 MACROLIDE ANTIBIOTICS GLAXO GROUP LIMITED (GB) 2002-06-27 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050215495-A1 Macrolide antibiotics IL1R1, MRPL12, RPS21 MEN1 2872/4885KMT2A 2302/4885SMN1; SMN2 3554/4885
US-20060211636-A1 Macrolide Antibiotics IL1R1, MRPL12, RPS21 MEN1 2872/4885KMT2A 2302/4885SMN1; SMN2 3554/4885
US-20040077557-A1 Macrolide antibiotics MALT1, MRPL21, IL1R1 MEN1 2870/4885KMT2A 2312/4885SMN1; SMN2 3041/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.